Research Article
Treatment of Recurrent Focal Segmental Glomerulosclerosis
in Pediatric Kidney Transplant Recipients: Effect of Rituximab
Table 1
Clinical features of cases of pediatric recurrent FSGS.
| | Case 1 | Case 2 | Case 3 | Case 4 |
| | Age at transplant | 13 | 13 | 17 | 18 | | Sex | F | M | F | M | | Ethnicity | Black | Asian | Hispanic | Hispanic | | Donor | DD | DD | DD | DD | | PP start (days posttxp) | 2 | 5 | 6 | 217 | | PP duration (days) | 540 | 93 | 485 | 527 | | Rituximab start (days posttxp) | 10 | 14 | 395 | 267 | | Urine UP/C Pre-PP | 5.8 | 25–44 | 11 | 20 | | Urine UP/C nadir | 0.8 | 0.1 | 0.2 | 0.18 | | Urine UP/C current | 1.8 | 0.1 | 0.2 | 10.7 | | Current eGFR (mL/min/1.73 m2) | 113 | 127 | 88 | 106 | | Follow-up postrituximab (months) | 23 | 22 | 24 | 22 | | Current PP | No | No | No | Yes |
|
|
F: female; M: male; DD: deceased donor; PP: plasmapheresis; UP/C: urine protein to creatinine ratio.
|
